Citations 3
American Society of Hematology: building a comprehensive minority recruitment and retention professional program
Rollins, Margo , Warsame, Rahma , Smith, Melody , Rouce, Rayne H. , Avalos, Belinda R. , Johnson, Cage S., López, José A. , Thompson, Alexis A. , Fanning, Lisa, Frustace, Patricia, Roche, Keelin F. , Havre, Nathalie van , Mack, Devon, Flowers, Christopher R. , Rollins, Margo R , Warsame, Rahma , Thompson, Alexis A , Terrell, Deirdra R , Smith, Melody , Molina, Arturo , Terrell, Deirdra R.
Blood Advances | November 21, 2024 | Volume: 8 | Issue: 24 | Pages: 6237-6247
10.1182/bloodadvances.2024013519
Abstract In 2003, the Institute of Medicine noted the need to improve workforce diversity. The American Society of Hematology (ASH) responded by developing the Minority Recruitment Initiative (MRI) to recruit diverse physicians/scientists into hematology. We evaluated the outcomes of the program. From 2004 to 2022, there were 405 awardees. Compared with national estimates, MRI awardees were less likely to discontinue their degree programs. MRI graduate student awardees had 0% attrition (97.5% confidence interval [CI], 10.6), whereas the national minority graduate student attrition was 36%. Medical student awardees had 2.2% (95% CI, 0.61-5.6) attrition, compared with the minority medical school attrition of 5.6%. Awardees were more likely than expected to pursue hematology-oncology (5.7% minority national estimate) because 14.4% (95% CI, 8.1-23.0) of medical student awardees and 88.5% (95% CI, 70.0-97.6) of early career awardees remain in the field. ASH has developed a successful program, but continued efforts are needed to advance equity in hematology.
Survival following allogeneic transplant in patients with myelofibrosis
Gowin, Krisstina , Ballen, Karen K. , Ahn, Kwang Woo , Hu, Zhen‐Huan , Ali, Haris , Arcasoy, Murat O. , Devlin, Rebecca, Coakley, Maria , Gerds, Aaron T. , Jain, Tania , Kandarpa, Malathi , Komrokji, Rami S. , Luber, Kierstin, Michaelis, Laura C. , Patches, Sarah, Pariser, Ashley, Rampal, Raajit K. , Stein, Brady L. , Verstovšek, Srđan , Wadleigh, Martha , Aljurf, Mahmoud , Avalos, Belinda R. , Bashey, Asad, Beitinjaneh, Amer , Černý, Jan , Copelan, Edward A. , DeFilipp, Zachariah , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hashmi, Shahrukh K. , Kharfan‐Dabaja, Mohamed A. , Kindwall‐Keller, Tamila L. , Kröger, Nicolaus , Litzow, Mark R. , Marks, David I. , Nathan, Sunita , Pawarode, Attaphol , Rowe, Jacob M. , Savoie, Mary Lynn , Seo, Sachiko , Solh, Melhem , Tamari, Roni , Verdonck, Leo F. , Alyea, Edwin P. , Sobecks, Ronald , Scott, Bart L. , Nakamura, Ryotaro , Saber, Wael , Kroger, Nicolaus , Davenport, Ashley Pariser , Gerds, Aaron T , Jain, Tania , Gadalla, Shahinaz M , Verstovsek, Srdan , Komrokji, Rami S , Kroger, Nicolaus , Kröger, Nicolaus , Green, Michael, Gupta, Vikas , Hobbs, Gabriela , Kuykendall, Andrew , Masárová, Lucia , Talpaz, Moshe , Agrawal, Vaibhav , Díaz, Miguel Ángel , Bacher, Ulrike , Chhabra, Saurabh , Cutler, Corey S. , Grunwald, Michael R. , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Olsson, Richard F. , Savani, Bipin N. , Yared, Jean A. , Popat, Uday R , Mesa, Ruben A.
Blood Advances | May 8, 2020 | Volume: 4 | Issue: 9 | Pages: 1965-1973
10.1182/bloodadvances.2019001084
Abstract Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
Copelan, Edward A. , Hamilton, Betty K. , Avalos, Belinda R. , Ahn, Kwang Woo , Bolwell, Brian J., Zhu, Xiaochun , Aljurf, Mahmoud , Bredeson, Christopher , Cahn, Jean‐Yves , Costa, Luciano J. , Hale, Gregory A., Halter, Joerg , Inamoto, Yoshihiro , Kamble, Rammurti T., Litzow, Mark R. , Loren, Alison W. , Marks, David I. , Olavarría, Eduardo, Sabloff, Mitchell , Seftel, Matthew D. , Schouten, Harry C. , Üstün, Celalettin , Waller, Edmund K. , Weisdorf, Daniel J. , Wirk, Baldeep , Horowitz, Mary M. , Arora, Mukta , Cortes, Jörge E. , Kalaycio, Matt, Saber, Wael , Halter, Jörg , Besien, Koen van , Lima, Marcos de , Gale, Robert Peter , Hamadani, Mehdi , Roy, Vivek , Savani, Bipin N. , Szer, Jeff , Maziarz, Richard Thomas , Waller, Edmund K , Weisdorf, Dan , Cortes, Jorge , Costa, Luciano J , Sabloff, Mitchell
Blood | September 25, 2013 | Volume: 122 | Issue: 24 | Pages: 3863-3870
Key Points In combination with cyclophosphamide, intravenous busulfan is associated with better leukemia-free and overall survival in AML than TBI.